Safety and efficacy of envafolimab combined with FOLFOX as first-line treatment in patients with locally advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma in a phase Ⅱ clinical trial

LIU Rong-rui; YIN Xian-li; DENG Yan-hong; XU Nong; XIANG Si-long; ZHANG Yun; GONG Zhao-long; LIU Dong-fang; XU Jian-ming

doi:10.3969/j.issn.1003-3734.2022.15.009

Home>Articles>Safety and efficacy of envafolimab combined with FOLFOX as first-line treatment in patients with locally advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma in a phase Ⅱ clinical trial

DOI: 10.3969/j.issn.1003-3734.2022.15.009

Safety and efficacy of envafolimab combined with FOLFOX as first-line treatment in patients with locally advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma in a phase Ⅱ clinical trial

LIU Rong-rui

YIN Xian-li

DENG Yan-hong

XU Nong

XIANG Si-long

ZHANG Yun

GONG Zhao-long

LIU Dong-fang

XU Jian-ming

Machine-generated Keywords：

Publication Date：2022-08-15

Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)

Pages：7( 1502-1508 )

Chinese Journal of New Drugs

ISTICPKU

ISSN：1003-3734

Year, Vol.(Issue)：2022,31(15)